Cirrhosis clinical trials at UC Davis
5 research studies open to eligible people
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
open to eligible people ages 18 years and up
This is a 5-year, longitudinal, observational study of patients with PBC designed to specifically address important clinical questions that remain incompletely answered from registration trials. In addition to the study database, a bio specimen repository will also be included so that translational studies of genomics and biomarkers of response may be performed.
Sacramento, California and other locations
A Study of Experimental Obeticholic Acid For Primary Biliary Cholangitis (inflammation and scarring of liver bile ducts)
open to eligible people ages 18 years and up
Primary Biliary Cholangitis (PBC) is a serious, life-threatening, bile acid related liver disease of unknown cause. Without treatment, it frequently progresses to liver fibrosis and eventual cirrhosis requiring liver transplantation or resulting in death. The investigational drug, Obeticholic Acid (OCA) is a modified bile acid and FXR agonist that is derived from the primary human bile acid chenodeoxycholic acid. The key mechanisms of action of OCA, including its choleretic, anti-inflammatory, and anti-fibrotic properties, underlie its hepatoprotective effects and result in attenuation of injury and improved liver function in a cholestatic liver disease such as PBC. The study will assess the effect of OCA compared to placebo, combined with stable standard care, on clinical outcomes in PBC patients.
Sacramento, California and other locations
A Study of Experimental Seladelpar in Patients With Primary Biliary Cholangitis (disease that damages the bile ducts in the liver)
“This research study measures the effectiveness and safety of Seladelpar (or MBX-8025) in treating patients with Primary Biliary Cholangitis.”
open to eligible people ages 18-75
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)
Sacramento, California and other locations
A Study of the Experimental Medicine Obeticholic Acid For Nonalcoholic Steatohepatitis (NASH) (accumulation of liver fat)
open to eligible people ages 18 years and up
The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747) can lead to histological improvement in fibrosis with no worsening of NASH in adults with compensated cirrhosis due to NASH.
Sacramento, California and other locations
Do you have Fatty Liver or NASH with scars and damage to the liver (cirrhosis)? Participate in a study
“We are evaluating a new investigational medicine in the treatment of NASH (Fatty Liver) cirrhosis with or without complications”
open to eligible people ages 18 years and up
This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of emricasan in improving event-free survival based on a composite clinical endpoint (where all-cause mortality, new decompensation events, and MELD score progression are events) in subjects with decompensated NASH cirrhosis.
Sacramento, California and other locations
Last updated: